SANTA MONICA, Calif., Dec. 1, 2011 /PRNewswire/ -- Agensys, Inc. ("Agensys"), a subsidiary of Astellas (Tokyo:4503,"Astellas") has announced that Frank P. Hudson has been appointed vice president of finance, while Wolfgang Noe, Ph.D., has been named vice president of process sciences and manufacturing.
"Frank and Wolfgang each bring a wealth of experience from the biopharma industry to their respective positions," said Sef Kurstjens, M.D., Ph.D., president and chief executive officer of Agensys. "Frank's experience in research and development finance is exactly what we were looking for in our candidates, and Wolfgang's record in preclinical and clinical drug development brings additional strength to our operations. We are looking forward to their contributions at Agensys."
Astellas acquired Agensys in 2007. Based in Santa Monica, Calif., Agensys is the company's center of antibody product discovery and development operations. A state-of-the-art research and development facility is scheduled for completion in 2013.
Agensys has a rich pipeline that includes four monoclonal antibody products in clinical trials: (1) AGS-1C4D4, directed to Prostate Stem Cell Antigen (PSCA), a target for prostate, pancreatic, and bladder cancers; (2) ASG-5ME, Agensys' first antibody-drug conjugate (ADC), directed to AGS-5, a target in multiple epithelial tumors; (3) AGS-16M8F, an ADC developed for the treatment of metastatic renal cancer; and (4) AGS-22M6E, an ADC developed for multiple solid tumors to include breast, bladder, lung, and pancreatic cancers. Agensys' preclinical pipeline encompasses over 10 different monoclonal antibodies (MAbs) programs. Both ASG-5ME and AGS-22M6E are co-developed with Seattle Genetics.
Hudson joins Agensys from the Mannkind Corporation where he served as vice president of finance since 2007. During a career in the pharmaceutical industry spanning more than 20 years, Hudson headed fiscal management for research and developm
Copyright©2010 PR Newswire.
All rights reserved